EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access

Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged

Mohammad Reza Movahed

EuroIntervention · 2024

DOI: 10.4244/eij-d-23-00830 ↗

Kurz gefasst

Leserbrief in der Zeitschrift EuroIntervention, 2024. Verfasst von Mohammad Reza Movahed. Beteiligte Einrichtung: Department of Medicine, University of Arizona, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Vascular Diseases, Coronary Occlusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionVascular DiseasesCoronary OcclusionHumansChronic DiseaseTreatment OutcomeCoronary AngiographyRisk Factors

Autor:innen und Institutionen

  • Department of Medicine, University of Arizona, Tucson, AZ, USA.

Zitieren

APA

Movahed, M. R. (2024). Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged. EuroIntervention. https://doi.org/10.4244/eij-d-23-00830

Vancouver

Movahed MR. Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged. EuroIntervention. 2024. doi:10.4244/eij-d-23-00830

BibTeX
@article{Movahed2024,
  author = {Movahed, Mohammad Reza},
  title = {Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged},
  journal = {EuroIntervention},
  year = {2024},
  doi = {10.4244/eij-d-23-00830}
}
Kostenlos starten →